Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.

Sophia H VerspohlTobias HolderriedCharlotte BehningPeter BrossartValentin Sebastian Schäfer

Published in: Therapeutic advances in musculoskeletal disease (2021)

Rh-irAEs occur under ICI therapy, especially in patients with higher tumour response. However, they are not the most frequent irAE after ICI exposure: 9.3% of all irAEs were rheumatic (20 rh-irAE cases in 19 patients of a total of 215 irAE cases in 163 patients).

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
rheumatoid arthritis
peritoneal dialysis
stem cells
risk factors
patient reported outcomes